XML 63 R35.htm IDEA: XBRL DOCUMENT
v3.20.1

License and Collaboration Agreement (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | ---
Dec. 31, 2019 | Mar. 31, 2020 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2019 | May 07, 2019 | Jul. 13, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront payments and fees | $ 23,792 | $ 20,415 |  |  | $ 23,792 |  |
Revenue recognized |  | 1,200 |  | $ 1,200 |  |  |
Receivable from collaboration partner and contract asset - related party | 6,755 | $ 3,594 |  |  | 6,755 |  |
Transaction price | 112,900 |  |  |  | $ 112,900 |  |
License and Collaborative Revenue |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Development cost |  |  |  |  | 20.00% |  |
Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Development cost |  | 80.00% |  |  |  |  |
Second Generation Analog Phase 2 Cd Clinical Trial Primary Clinical |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Development cost |  | 80.00% |  |  |  |  |
First Amendment | Development, regulatory and sales milestone payments |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Eligible payment receivable |  |  |  |  |  | $ 1,000,000 |
Janssen Biotech, Inc. | License and Collaborative Revenue |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Revenue recognized |  | $ 3,600 |  | 1,600 |  |  |
Transaction price |  | $ 113,600 |  |  |  |  |
Development cost |  | 80.00% |  |  |  |  |
Increase (decrease) in transaction price |  | $ 700 |  |  |  |  |
Janssen Biotech, Inc. | Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Development cost |  | 20.00% |  |  |  |  |
Janssen Biotech, Inc. | License and Collaboration Agreement |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Transaction price recognized based on proportional performance |  | $ 4,335 |  | $ 1,564 |  |  |
Janssen Biotech, Inc. | License and Collaboration Agreement | Upfront cash payment |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront payments and fees |  |  |  |  |  |  | $ 50,000
Janssen Biotech, Inc. | First, second-generation compound | Milestone payment |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Amount payable upon the effectiveness of the First Amendment |  |  |  |  | $ 7,500 |  |
Janssen Biotech, Inc. | First, second-generation compound | Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Research program cost |  | 100.00% |  |  |  |  |
Janssen Biotech, Inc. | Second and third, second-generation compounds | Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Research program cost |  | 50.00% |  |  |  |  |
Janssen Biotech, Inc. | Thereafter | Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Research program cost |  | 100.00% |  |  |  |  |
Janssen Biotech, Inc. | Second-Generation Phase 2b Milestone |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Amount payable upon the effectiveness of the First Amendment | $ 5,000 |  |  |  |  |  |
Janssen Biotech, Inc. | Second-Generation Phase 2b Milestone | Milestone payment |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Revenue recognized |  | $ 7,500 |  |  |  |  |
Janssen Biotech, Inc. | Phase 2 clinical trial |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Amount payable upon the effectiveness of the First Amendment |  | 50,000 |  |  |  |  |
Janssen Biotech, Inc. | Phase 2 clinical trial | License and Collaborative Revenue |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Revenue |  | 18,300 |  |  |  |  |
Janssen Biotech, Inc. | Phase 2 clinical trial | Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Development cost |  |  | 20.00% |  |  |  |
Janssen Biotech, Inc. | First Amendment |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Revenue recognized |  | 5,000 |  |  |  |  |
Increase (decrease) in transaction price |  |  |  |  | $ (9,400) |  |
Janssen Biotech, Inc. | First Amendment | License and Collaborative Revenue |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Revenue recognized |  |  | $ 25,000 |  |  |  |
Janssen Biotech, Inc. | First Amendment | PTG-200, Phase 3 CD Clinical Trial Primary Clinical Endpoint |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Eligible payment receivable |  |  |  |  |  | 100,000 |
Janssen Biotech, Inc. | First Amendment | Second-Generation Analog, Phase 3 CD Clinical Trial Primary Clinical Endpoint [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Amount payable upon the effectiveness of the First Amendment |  | 50,000 |  |  |  |  |
Eligible payment receivable |  |  |  |  |  | $ 115,000 |
Janssen Biotech, Inc. | Amended First Opt-in | Upfront cash payment |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Amount payable upon the effectiveness of the First Amendment |  | 50,000 |  |  |  |  |
Janssen Biotech, Inc. | Amended Second Opt-in | Upfront cash payment |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Amount payable upon the effectiveness of the First Amendment |  | 50,000 |  |  |  |  |
Janssen Biotech, Inc. | Estimated variable consideration | License and Collaborative Revenue |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Revenue |  | 15,300 |  |  |  |  |
Janssen Biotech, Inc. | Pro Forma | License and Collaborative Revenue |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Revenue recognized |  |  | 25,000 |  |  |  |
Janssen Biotech, Inc. | Pro Forma | Milestone payment |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Revenue recognized |  |  | $ 25,000 |  |  |  |
Janssen Biotech, Inc. | Pro Forma | First Opt-in Election |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Former opt-in payments |  | 125,000 |  |  |  |  |
Janssen Biotech, Inc. | Pro Forma | Second Opt-in Election |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Former opt-in payments |  | $ 200,000 |  |  |  |  |

X
- Definition Represents the amount of former opt-in revenue eligible to receive. + References No definition available. + Details
Name: | ptgx_CollaborativeArrangementFormerOptInRevenueEligibleToReceive
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment payable upon the effectiveness of the First Amendment + References No definition available. + Details
Name: | ptgx_CollaborativeArrangementPayableUponEffectivenessOfAmendment
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of development cost incurred. + References No definition available. + Details
Name: | ptgx_CollaborativeArrangementPercentageOfDevelopmentCostsIncurred
Namespace Prefix: | ptgx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of research program cost incurred. + References No definition available. + Details
Name: | ptgx_CollaborativeArrangementPercentageOfResearchProgramCostsIncurred
Namespace Prefix: | ptgx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent Consideration Receivable + References No definition available. + Details
Name: | ptgx_ContingentConsiderationReceivable
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Deduction in the amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References No definition available. + Details
Name: | ptgx_ContractWithCustomerLiabilityDeduction
Namespace Prefix: | ptgx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(11)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_DueFromRelatedPartiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_ProductOrServiceAxis=ptgx_LicenseAndCollaborativeRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ptgx_SecondGenerationAnalogPhase3CdClinicalTrialPrimaryClinicalEndpointMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ptgx_SecondGenerationAnalogPhase2CdClinicalTrialPrimaryClinicalEndpointMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_LicenseAndCollaborativeAgreementAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ptgx_DevelopmentRegulatoryAndSalesMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptgx_JanssenBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ptgx_UpfrontCashPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_CollaborationAgreementTrancheThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ptgx_MilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_CollaborationAgreementTrancheFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_CollaborationAgreementTrancheFiveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_SecondGenerationDevelopmentCompoundMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_PhaseTwoClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ptgx_Ptg200Phase3CdClinicalTrialPrimaryClinicalEndpointMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_AmendedCollaborationAgreementTrancheOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_AmendedSecondOptInMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_EstimatedVariableConsiderationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ProFormaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_CollaborationAgreementTrancheOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptgx_CollaborationAgreementTrancheTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |